SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of ...

Source: Journal of Hematology and Oncology - July 28, 2020 Category: Hematology Authors: Yu Chen, Min Gao, Zhaoqin Huang, Jinming Yu and Xiangjiao Meng Tags: Review Source Type: research